Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multi-Centre Study to Evaluate the Safety, Tolerability and Immunogenicity of CSL's Influenza Vaccine in a Paediatric Population (greater than or equal to 6 Months to less than 9 Years of Age).

Next Previous
X
Search
Trial Profile

An Open-Label, Multi-Centre Study to Evaluate the Safety, Tolerability and Immunogenicity of CSL's Influenza Vaccine in a Paediatric Population (greater than or equal to 6 Months to less than 9 Years of Age).

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 May 2019

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Influenza virus vaccine (Afluria) (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions
  • Sponsors CSL

    • Most Recent Events

    • 29 Mar 2019 Results comparing the rates of fever observed in children (aged 6 months to <18 years) in the three studies of S-IIV3/S-IIV4 (NCT02212106, NCT02545543 and NCT02914275) prepared using the modified manufacturing process and 3 historical formulation studies: two single-arm studies (FLU-04-05 ; USF-06-29 and one blinded, comparator-controlled study USF-07-36) published in the Vaccine
    • 14 Jul 2008 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top